We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

9 hedge funds and large institutions have $5.31M invested in Moleculin Biotech in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

571% more capital inflows, than outflows

Capital inflows: $3.32M | Capital outflows: $494K

1.86% more ownership

Funds ownership: 7.54% → 9.4% (+1.9%)

18% less funds holding

Funds holding: 11 → 9 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.28M
2
Renaissance Technologies
Renaissance Technologies
New York
+$870K
3
BlackRock
BlackRock
New York
+$109K
4
Morgan Stanley
Morgan Stanley
New York
+$54.4K

Top Sellers

Rank Fund Capital Flow
1
CVI Holdings
CVI Holdings
Delaware
-$294K
2
Armistice Capital
Armistice Capital
New York
-$179K
3
Bank of America
Bank of America
North Carolina
-$20K
4
Icon Wealth Partners
Icon Wealth Partners
Texas
-$1K

MBRX Hedge Fund Activity: Q2 2019 in Review

9 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2019, worth a combined $5.31M — up 198% from $1.78M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of MBRX and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $2.28M. The largest seller was CVI Holdings, exiting entirely with an estimated $294K sold.

  • 9 institutional investors held Moleculin Biotech (MBRX) as of Q2 2019, down from 11 in Q1 2019.
  • Funds reported $5.31M of Moleculin Biotech stock for Q2 2019, up 198% quarter-over-quarter.
  • 1 fund opened new Moleculin Biotech positions in Q2 2019 and 3 closed out, a net change of -2 holders.
  • The largest Moleculin Biotech buyer in Q2 2019 was Vanguard Group, an estimated $2.28M added.
  • The largest Moleculin Biotech seller in Q2 2019 was CVI Holdings, an estimated $294K sold.

Based on aggregated 13F filings for Q2 2019.